Literature DB >> 1903310

Hemophilia treatment in historical perspective: a review of medical and social developments.

F R Rosendaal1, C Smit, E Briët.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1903310     DOI： 10.1007/bf01714977

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  116 in total

1.  HIGH-POTENCY ANTIHAEMOPHILIC FACTOR CONCENTRATE PREPARED FROM CRYOGLOBULIN PRECIPITATE.

Authors:  J G POOL; E J GERSHGOLD; A R PAPPENHAGEN
Journal:  Nature       Date:  1964-07-18       Impact factor: 49.962

2.  Activated prothrombin concentrate for patients with factor VIII inhibitors.

Authors:  E M Kurczynski; J A Penner
Journal:  N Engl J Med       Date:  1974-07-25       Impact factor: 91.245

3.  Jaundice and antibodies directed against factors 8 and 9 in patients treated for haemophilia or Christmas disease in the United Kingdom.

Authors:  R Biggs
Journal:  Br J Haematol       Date:  1974-03       Impact factor: 6.998

4.  Prophylactic therapy in classical hemophilia: a preliminary report.

Authors:  P M Robinson; P Tittley; R K Smiley
Journal:  Can Med Assoc J       Date:  1967-09-09       Impact factor: 8.262

5.  Haemophilia in Sweden. III. Symptomatology, with special reference to differences between haemophilia A and B.

Authors:  O RAMGREN
Journal:  Acta Med Scand       Date:  1962-02

6.  Absence of hepatitis after treatment with a pasteurized factor VIII concentrate in patients with hemophilia and no previous transfusions.

Authors:  K Schimpf; P M Mannucci; W Kreutz; H H Brackmann; G Auerswald; N Ciavarella; J Mösseler; V DeRosa; B Kraus; C Brueckmann
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

7.  [Causes of death in hemophilia patients in East Germany].

Authors:  W G Schiller; G Hartmann; W Remde
Journal:  Folia Haematol Int Mag Klin Morphol Blutforsch       Date:  1985

8.  Changes in the life expectancy of patients with severe haemophilia A in Finland in 1930-79.

Authors:  E Ikkala; T Helske; G Myllylä; H R Nevanlinna; P Pitkänen; V Rasi
Journal:  Br J Haematol       Date:  1982-09       Impact factor: 6.998

9.  Supervised patient-management of hemophilia. A study of 45 patients with hemophilia A and B.

Authors:  P H Levine; A F Britten
Journal:  Ann Intern Med       Date:  1973-02       Impact factor: 25.391

10.  Factor VIII:C concentrate purified from plasma using monoclonal antibodies: human studies.

Authors:  D B Brettler; A D Forsberg; P H Levine; J Petillo; K Lamon; J L Sullivan
Journal:  Blood       Date:  1989-05-15       Impact factor: 22.113
View more
  17 in total

Review 1.  Progress and challenges in the development of a cell-based therapy for hemophilia A.

Authors:  M E Fomin; P P Togarrati; M O Muench
Journal:  J Thromb Haemost       Date:  2014-10-31       Impact factor: 5.824

2.  The human clotting factor VIII cDNA contains an autonomously replicating sequence consensus- and matrix attachment region-like sequence that binds a nuclear factor, represses heterologous gene expression, and mediates the transcriptional effects of sodium butyrate.

Authors:  F J Fallaux; R C Hoeben; S J Cramer; D J van den Wollenberg; E Briët; H van Ormondt; A J van Der Eb
Journal:  Mol Cell Biol       Date:  1996-08       Impact factor: 4.272

3.  Expression of human blood clotting factor VIII in the mammary gland of transgenic sheep.

Authors:  H Niemann; R Halter; J W Carnwath; D Herrmann; E Lemme; D Paul
Journal:  Transgenic Res       Date:  1999-06       Impact factor: 2.788

4.  Frequency of Specific and Non-specific Inhibitors in Haemophilia A Patients.

Authors:  Javeria Ashfaq; Faryal Tariq; Rehana Ahmed; Warkha Thakur; Madiha Abid; Munira Borhany
Journal:  Cureus       Date:  2022-06-16

5.  Long-term correction of hemophilia A mice following lentiviral mediated delivery of an optimized canine factor VIII gene.

Authors:  J M Staber; M J Pollpeter; C-G Anderson; M Burrascano; A L Cooney; P L Sinn; D T Rutkowski; W C Raschke; P B McCray
Journal:  Gene Ther       Date:  2017-09-14       Impact factor: 5.250

6.  The tertiary structure and domain organization of coagulation factor VIII.

Authors:  Betty W Shen; Paul Clint Spiegel; Chong-Hwan Chang; Jae-Wook Huh; Jung-Sik Lee; Jeanman Kim; Young-Ho Kim; Barry L Stoddard
Journal:  Blood       Date:  2007-10-26       Impact factor: 22.113

7.  Factor VIII and coronary heart disease.

Authors:  F R Rosendaal
Journal:  Eur J Epidemiol       Date:  1992-05       Impact factor: 8.082

Review 8.  A review of current methods for assessing hemostasis in vivo and introduction to a potential alternative approach.

Authors:  Mallory R Scola; Leslie M Baggesen; Tim C Nichols; Nigel S Key; Caterina M Gallippi
Journal:  Thromb Res       Date:  2012-03-08       Impact factor: 3.944

9.  Long-Term Follow-Up of a Portuguese Single-Centre Cohort of Persons with Haemophilia and Hepatitis C Virus Infection.

Authors:  Tiago Pereira Guedes; Mónica Garrido; Ricardo Kuttner Magalhães; Teresa Moreira; Marta Rocha; Luís Maia; José Manuel Ferreira; Sara Morais; Isabel Pedroto
Journal:  GE Port J Gastroenterol       Date:  2020-09-29

10.  First analysis of 10-year trends in national factor concentrates usage in haemophilia: data from CHARMS, the Canadian Hemophilia Assessment and Resource Management System.

Authors:  A N Traore; A K C Chan; K E Webert; N Heddle; B Ritchie; J St-Louis; J Teitel; D Lillicrap; A Iorio; I Walker
Journal:  Haemophilia       Date:  2014-07       Impact factor: 4.287
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.